SMMT Quote, Financials, Valuation and Earnings

Madrigal Pharmaceuticals, Inc. has a net margin of -- compared to Summit Therapeutics, Inc.'s net margin of -39.75%. Summit Therapeutics, Inc.'s return on equity of -283.98% beat Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56%.

Summit Therapeutics, Inc. has a consensus price target of $32.52, signalling upside risk potential of 86.47%. On the other hand Madrigal Pharmaceuticals, Inc. has an analysts' consensus of $603.47 which suggests that it could grow by 2.56%. Given that Summit Therapeutics, Inc. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe Summit Therapeutics, Inc. is more attractive than Madrigal Pharmaceuticals, Inc..

Summit Therapeutics, Inc. has a beta of -1.504, which suggesting that the stock is 250.379% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals, Inc. has a beta of -1.001, suggesting its less volatile than the S&P 500 by 200.123%.

Summit Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Summit Therapeutics, Inc. pays -- of its earnings as a dividend. Madrigal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Summit Therapeutics, Inc. quarterly revenues are --, which are smaller than Madrigal Pharmaceuticals, Inc. quarterly revenues of $287.3M. Summit Therapeutics, Inc.'s net income of -$231.8M is lower than Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M. Notably, Summit Therapeutics, Inc.'s price-to-earnings ratio is -- while Madrigal Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics, Inc. is 21,812.02x versus 17.62x for Madrigal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Terns Pharmaceuticals, Inc. has a net margin of -- compared to Summit Therapeutics, Inc.'s net margin of --. Summit Therapeutics, Inc.'s return on equity of -283.98% beat Terns Pharmaceuticals, Inc.'s return on equity of -29.05%.

Summit Therapeutics, Inc. has a consensus price target of $32.52, signalling upside risk potential of 86.47%. On the other hand Terns Pharmaceuticals, Inc. has an analysts' consensus of $53.56 which suggests that it could grow by 36.66%. Given that Summit Therapeutics, Inc. has higher upside potential than Terns Pharmaceuticals, Inc., analysts believe Summit Therapeutics, Inc. is more attractive than Terns Pharmaceuticals, Inc..

Summit Therapeutics, Inc. has a beta of -1.504, which suggesting that the stock is 250.379% less volatile than S&P 500. In comparison Terns Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Summit Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Terns Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Summit Therapeutics, Inc. pays -- of its earnings as a dividend. Terns Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Summit Therapeutics, Inc. quarterly revenues are --, which are smaller than Terns Pharmaceuticals, Inc. quarterly revenues of --. Summit Therapeutics, Inc.'s net income of -$231.8M is lower than Terns Pharmaceuticals, Inc.'s net income of -$24.6M. Notably, Summit Therapeutics, Inc.'s price-to-earnings ratio is -- while Terns Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics, Inc. is 21,812.02x versus -- for Terns Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Travere Therapeutics, Inc. has a net margin of -- compared to Summit Therapeutics, Inc.'s net margin of 15.59%. Summit Therapeutics, Inc.'s return on equity of -283.98% beat Travere Therapeutics, Inc.'s return on equity of -263.9%.

Summit Therapeutics, Inc. has a consensus price target of $32.52, signalling upside risk potential of 86.47%. On the other hand Travere Therapeutics, Inc. has an analysts' consensus of $41.6429 which suggests that it could grow by 9.27%. Given that Summit Therapeutics, Inc. has higher upside potential than Travere Therapeutics, Inc., analysts believe Summit Therapeutics, Inc. is more attractive than Travere Therapeutics, Inc..

Summit Therapeutics, Inc. has a beta of -1.504, which suggesting that the stock is 250.379% less volatile than S&P 500. In comparison Travere Therapeutics, Inc. has a beta of 0.846, suggesting its less volatile than the S&P 500 by 15.379%.

Summit Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Travere Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Summit Therapeutics, Inc. pays -- of its earnings as a dividend. Travere Therapeutics, Inc. pays out -- of its earnings as a dividend.

Summit Therapeutics, Inc. quarterly revenues are --, which are smaller than Travere Therapeutics, Inc. quarterly revenues of $164.9M. Summit Therapeutics, Inc.'s net income of -$231.8M is lower than Travere Therapeutics, Inc.'s net income of $25.7M. Notably, Summit Therapeutics, Inc.'s price-to-earnings ratio is -- while Travere Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics, Inc. is 21,812.02x versus 7.94x for Travere Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Viridian Therapeutics, Inc. has a net margin of -- compared to Summit Therapeutics, Inc.'s net margin of -49.03%. Summit Therapeutics, Inc.'s return on equity of -283.98% beat Viridian Therapeutics, Inc.'s return on equity of -47.79%.

Summit Therapeutics, Inc. has a consensus price target of $32.52, signalling upside risk potential of 86.47%. On the other hand Viridian Therapeutics, Inc. has an analysts' consensus of $41.25 which suggests that it could grow by 36.59%. Given that Summit Therapeutics, Inc. has higher upside potential than Viridian Therapeutics, Inc., analysts believe Summit Therapeutics, Inc. is more attractive than Viridian Therapeutics, Inc..

Summit Therapeutics, Inc. has a beta of -1.504, which suggesting that the stock is 250.379% less volatile than S&P 500. In comparison Viridian Therapeutics, Inc. has a beta of 0.945, suggesting its less volatile than the S&P 500 by 5.488%.

Summit Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viridian Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Summit Therapeutics, Inc. pays -- of its earnings as a dividend. Viridian Therapeutics, Inc. pays out -- of its earnings as a dividend.

Summit Therapeutics, Inc. quarterly revenues are --, which are smaller than Viridian Therapeutics, Inc. quarterly revenues of $70.6M. Summit Therapeutics, Inc.'s net income of -$231.8M is lower than Viridian Therapeutics, Inc.'s net income of -$34.6M. Notably, Summit Therapeutics, Inc.'s price-to-earnings ratio is -- while Viridian Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics, Inc. is 21,812.02x versus 34.64x for Viridian Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.